Summary & Overview
HCPCS J2782: Avacincaptad Pegol Injection, 0.1 mg
HCPCS Level II code J2782 designates the injectable medication avacincaptad pegol at a unit dose of 0.1 mg. This code matters nationally as it standardizes billing for a specific biologic formulation used in outpatient settings, supporting consistent reimbursement, utilization tracking, and clinical documentation. Accurate use of J2782 affects claims processing, payer coverage determinations, and provider revenue for treatments requiring this agent.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how these payers typically approach coverage and payment for specialty injectable agents and where policy variations commonly arise.
Readers will learn the clinical and billing context for J2782, expected sites of service, and which stakeholders are most relevant for prior authorization and claims adjudication. The report summarizes common benchmarks for unit-based drug codes, highlights policy considerations that commonly affect access and reimbursement for injectable biologics, and identifies data gaps where national guidance or payer policy language is often needed. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J2782 represents an injection of avacincaptad pegol, dosed at 0.1 mg per billing unit. This code is used for the administration of the specified injectable medication.
Service Type: Drug administration / Injectable biologic
Typical Site of Service: Outpatient infusion or ophthalmology clinic
Clinical & Coding Specifications
Clinical Context
A typical patient is an older adult with neovascular (wet) age-related macular degeneration (AMD) or a related choroidal neovascularization disorder presenting to an ophthalmology clinic or ambulatory surgical center for intravitreal therapy. The patient has visual distortion, decreased central vision, or subretinal fluid on optical coherence tomography (OCT). After clinical evaluation by a retinal specialist, the decision is made to administer an intravitreal injection of avacincaptad pegol (a complement factor C5 inhibitor) dosed and billed per J2782 (0.1 mg units). The clinical workflow includes informed consent, baseline visual acuity and intraocular pressure measurement, topical anesthesia and antisepsis, sterile draping and eyelid speculum placement, the intravitreal injection itself, post‑injection intraocular pressure check, and patient discharge with post‑procedure instructions and follow‑up OCT and clinic visits. The typical site of service is an ophthalmology clinic procedure room or ambulatory surgical center. Common scenarios include initial injection, scheduled repeat injections, or treatment for an active choroidal neovascular membrane not adequately controlled by other anti‑VEGF agents.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier |